350 rub
Journal Technologies of Living Systems №8 for 2011 г.
Article in number:
Clinical Prospects of the Study of NF-κB Signaling Pathway Components Expression and Activity iN tHE Tumors of Breast Cancer Patients
Keywords: nuclear transcription factor NF-kappa B NF-nuclear transcription factor NF-kappa B NF-&#61547 Bp65 NF-&#61547 Bp50 I&#61547 B&#61537 protein kinase Akt1 steroid hormone receptors HER2/neu breast cancer hormone sensitivity resistanceBp65 NF-&#954 Bp50 I&#954 B&#945 protein kinase Akt1 steroid hormone receptors HER2/neu breast cancer hormone sensitivity resistance
Authors:
E.S. Gershtein, A.M. Scherbakov, A.A. Tuleuova, L.K. Ovchinnikova, N.E. Kushlinskii
Abstract:
Contemporary knowledge about the molecular mechanisms of breast cancer development and progression and its sensitivity or resistance to various drugs allows to proceed from standardized averaged therapy regimens to so called "personalized medicine", i.e. to the prescription of treatment according to the individual patient-s features and biological characteristics of the tumor. One of the promising breast cancer molecular markers according to experimental data is polyfunctional nuclear transcription factor NF-B that plays an important role in cellular proliferation, apoptosis, inflammatory and autoimmune reactions by regulation of the expression of the genes involved in these processes. The aim of this study was a comparative evaluation of NF-kB p65 and p50, its IkBα inhibitor, and upstream effector protein kinase Akt1 expression (total content) and/or activation state in human breast cancer and adjacent histologically unchanged mammary gland tissues in relation to receptor status and main clinico-pathologic factors. 119 breast cancer patients were enclosed in the study. Markers - concentrations were measured by quantitative enzyme immunoassays using standard ELISA kits. It was demonstrated that in more than 90% of human breast cancers a coordinate increase of NF-kBp65 and p50 DNA-binding activities is observed. Total NF-kBp65, IkBa and effector protein kinase Akt1 concentrations are also increased. No significant associations between these markers and main breast cancer clinico-pathologic features including steroid receptors status were revealed, but the highest NF-kBp65 specific DNA-binding activity was found in the tumors with so called "triple receptor negative" receptor status that are resistant to both endocrine, and molecular targeted therapy. Hence, it is this specific group of patients that may benefit from the treatment with selective NF-kB inhibitors. Significant and practically universal increase of NF-kB subunits and regulators expression and activities in breast cancer as compared to adjacent unchanged mammary gland tissue indicates to a possible independent role of these markers in the prognosis of the disease course in general and its sensitivity to certain types of therapy
Pages: 14-23
References
  1. Кушлинский Н.Е., Герштейн Е.С., Овчинникова Л.К., Дигаева М.А. Биологические маркеры опухолей в клинике - достижения, проблемы, перспективы // Молекулярная медицина. 2008. № 3. С. 48 - 55.
  2. Герштейн Е.С, Кушлинский Н.Е., Давыдов М.И. Рецепторы семейства c-erbB как мишени молекулярно-направленной противоопухолевой терапии: достижения, проблемы, перспективы // Молекулярная медицина. 2010. № 4. С. 5 - 10.
  3. Герштейн Е.С., Овчинникова Л.К., Кушлинский Н.Е. Роль ядерного транскрипционного фактора NF-kappa B в этиологии, патогенезе и клиническом течении рака молочной железы // Вопросы биологической, медицинской и фармацевтической химии. 2009. № 5. С. 10 - 13.
  4. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB // J. Clin. Invest. 2001. V. 107. № 3. P. 241 - 246.
  5. Cao Y., Karin M. NF-kappaB in mammary gland development and breast cancer // J. Mammary Gland. Biol. Neoplasia. 2003. V. 8. № 2. P. 215 - 223.
  6. Adli M., Baldwin A.S. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation // J. Biol. Chem. 2006. V. 281. № 37. P.26976 - 26984.
  7. Zhou Y., Eppenberger-Castori S., Eppenberger U., Benz C.C. The NFkappaB pathway and endocrine-resistant breast cancer // Endocr. Relat. Cancer. 2005. V. 12. Suppl. 1. P. 37 - 46.
  8. Szoltysek K., Pietranek K., Kalinowska-Herok M., Pietrowska M., Kimmel M., Widlak P. TNFalpha-induced activation of NFkappaB protects against UV-induced apoptosis specifically in p53-pro¬ficient cells // Acta Biochim. Pol. 2008. V. 55. № 4. P. 741 - 748.
  9. Bhat-Nakshatri P., Sweeney C.J., Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells // Oncogene. 2002. V. 21. №13. P. 2066 - 2078.
  10. Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P., Baldwin A.S. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK // Genes Dev. 2008. V.22. № 11. P. 1490-1500.
  11. Sliva D., Rizzo M.T., English D. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator // J. Biol. Chem. 2002. V. 277. № 5. P. 3150 - 3157.
  12. Biswas D.K., Iglehart J.D. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer // J. Cell Physiol. 2006. V. 209. № 3. P. 645-652.
  13. Pratt M.A., Bishop T.E., White D., Yasvinski G., Menard M., Niu M.Y. et al. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence // Mol. Cell Biol. 2003. V. 23. № 19. P. 6887 - 6900.
  14. deGraffenried L.A., Chandrasekar B., Friedrichs W.E., Donzis E., Silva J., Hidalgo M. et al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen // Ann. Oncol. 2004. V. 15. № 6. P. 885 - 890.
  15. Zhou Y., Yau C., Gray J.W., Chew K., Dairkee S.H., Moore D.H. et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer // BMC Cancer. 2007. № 7. P. 59.
  16. Weldon C.B., Burow M.E., Rolfe K.W., Clayton J.L., Jaffe B.M., Beckman B.S. NF-kappa B-mediated chemoresistance in breast cancer cells // Surgery. 2001. V. 130. № 2. P. 143 - 150.
  17. Hernandez-Vargas H., Rodriguez-Pinilla S.M., Julian-Tendero M., Sanchez-Rovira P., Cuevas C., Anton A. et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance // Breast Cancer Res. Treat. 2007. V. 102. № 2. P. 157 - 172.
  18. Scherbakov A.M., Lobanova Y.S., Andreeva O.E., Shatskaya V.A., Krasil'nikov M.A. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin // Biosci. Rep. 2010. V. 31. № 2. P. 137 - 143.
  19. Ahmed K.M., Cao N., Li J.J. HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer // Anticancer Res. 2006. V. 26(6B). P. 4235 - 4243.
  20. Russo S.M., Tepper J.E., Baldwin A.S., Jr., Liu R., Adams J., Elliott P. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB // Int. J. Radiat. Oncol. Biol. Phys. 2001. V. 50. № 1. P. 183 - 193.
  21. Park B.K., Zhang H., Zeng Q., Dai J., Keller E.T., Giordano T. et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF // Nat. Med. 2007. V. 13. № 1. P. 62 - 69.
  22. Jones M.D., Liu J.C., Barthel T.K., Hussain S., Lovria E., Cheng D. et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes // Clin. Cancer Res. 2010. V. 16. № 20. P. 4978 - 4989.
  23. Xu J., Wu H.F., Ang E.S., Yip K., Woloszyn M., Zheng M.H. et al. NF-kappaB modulators in osteolytic bone diseases // Cytokine Growth Factor Rev. 2009. V. 20. № 1. P. 7 - 17.
  24. Zhou Y., Eppenberger-Castori S., Marx C., Yau C., Scott G.K., Eppenberger U. et al. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers // Int. J. Biochem. Cell Biol. 2005. V. 37. № 5. P. 1130 - 1144.
  25. Герштейн Е.С., Щербаков А.М., Платова А.М., Чемерис Г.Ю., Летягин В.П., Кушлинский Н.Е. Экспрессия и ДНК-связывающая активность ядерного транскрипционного фактора NF-kB в опухолях больных раком молочной железы // Бюллетень экспериментальной и биологической медицины. 2010. Т. 150. № 7. С. 80 - 84.
  26. Gershtein E.S., Shatskaya V.A., Ermilova V.D., Kushlinsky N.E., Krasil'nikov M.A. Phospatidylinositol 3-kinase expression in human breast cancer // Clin. Chim. Acta. 1999. V. 287. № 1-2. P. 59 - 67.
  27. Gershtein E.S., Scherbakov A.M., Shatskaya V.A., Kushlinsky N.E., Krasil'nikov M.A. Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations // Anticancer Res. 2007. V. 27(4A). P. 1777 - 1782.
  28. Gershtein E.S., Scherbakov A.M., Anurova O.A., Krasilnikov M.A, Kushlinsky N.E. Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopathological features and tumor VEGF-signaling system component levels // Int. J. Biol. Markers. 2006. V. 21. № 1. P. 12 - 19.
  29. Liu C., Zhou S., Ke C.S., Li N.P., Wu R.L. Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression // Ai Zheng. 2007. V. 26. № 9. P. 929 - 936.
  30. Van Laere S.J., Van der Auwera I., Van den Eynden G.G., van Dam P., Van Marck E.A., Vermeulen P.B. et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation // Br. J. Cancer. 2007. V. 97. № 5. P. 659 - 669.